OMGAQ — Omega Liquidating Share News
0.000.00%
Last trade - 00:00- $0.17m
- -$14.62m
- $3.09m
Brief: Omega Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Omega Therapeutics Reports FDA Clearance Of IND Application For OTX-2002
Brief: Omega Therapeutics Presents New Preclinical Data On Potential Hepatocellular Carcinoma Treatment At Conference
Omega Therapeutics up on seeking FDA clearance for cancer therapy study
Brief: Omega Therapeutics Submits IND Application For OTX-2002 For MYC Driven Hepatocellular Carcinoma
U.S. RESEARCH ROUNDUP-Eli Lilly, Gilead Sciences, Upwork
Brief: Omega Therapeutics Reports First Quarter 2022 Financial Results And Highlights Recent Company Progress
Brief: Omega Therapeutics Announces Appointment Of Joshua Reed As CFO
Brief: Omega Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Outlines Key Corporate Objectives For 2022
Brief: Omega Therapeutics Inc - On Dec 20, Co And Pacific Western Bank Entered Into Fourth Amendment To Loan And Security Agreement Dated March 9, 2018
Brief: Omega Therapeutics Reports Third Quarter 2021 Financial Results
Brief: Omega Therapeutics Announces Strategic Research Collaboration With Stanford University School Of Medicine
Brief: Omega Therapeutics Reports Second Quarter 2021 Financial Results
U.S. RESEARCH ROUNDUP- Immuneering, Matterport, Tenaya Therapeutics
Omega Therapeutics slips after popping 30% in Nasdaq debut
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:01 AM
Brief: Omega Therapeutics Pricing Of IPO Of 7.4 Mln Shares Of Its Common Stock At $17.00 Per Share
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:01 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 09:38 AM